natgillin/translations-raw huggingface dataset:
This medicinal product is for single use only; any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Ovaj je lijek namijenjen za jednokratnu primjenu; neupotrijebljeni lijek i sav otpadni materijal mora se odbaciti u skladu s lokalnim propisima.
This may impair your ability to drive or operate machinery.
To može utjecati na sposobnost upravljanja vozilima ili strojevima.
Tigecycline has decreased in vitro activity against Proteus, Providencia, and Morganella spp.
Tigeciklin in vitro ima smanjenu aktivnost protiv sojeva Proteus, Providencia i Morganella spp.
What Tygacil is and what it is used for What you need to know before you receive Tygacil How Tygacil is given
Što je Tygacil i za što se koristi Što morate znati prije nego počnete primati Tygacil Kako primjenjivati Tygacil Moguće nuspojave
• Your doctor will monitor you closely for the development of any other bacterial infections.
• Vaš će liječnik pažljivo pratiti hoćete li dobiti druge bakterijske infekcije.
Tigecycline is administered intravenously and therefore has 100 % bioavailability.
Tigeciklin se primjenjuje intravenski i stoga je bioraspoloživost 100%-tna.
• Low protein levels in the blood
• Niska razina proteina u krvi
Liver function tests, coagulation parameters, haematology parameters, amylase and lipase should be monitored prior to treatment initiation with tigecycline and regularly while on treatment.
Testovi funkcije jetre, koagulacijski parametri, hematološki parametri, amilaza i lipaza trebaju se pratiti prije početka liječenja tigeciklinom i redovito tijekom trajanja liječenja.
No overall differences in pharmacokinetics were observed between healthy elderly subjects and younger subjects (see section 4.2).
Općenito nisu opažene razlike u farmakokinetici između zdravih starijih ispitanika i mlađih ispitanika (vidjeti dio 4.2).
In addition, tigecycline did not show NADPH-dependency in the inhibition of CYP2C9, CYP2C19, CYP2D6 and CYP3A, suggesting the absence of mechanism-based inhibition of these CYP enzymes.
Dodatno, tigeciklin ne pokazuje ovisnost o NADPH pri inhibiranju CYP2C9, CYP2C19, CYP2D6 i CYP3A, što ukazuje na nepostojanje mehanizmom utemeljene inhibicije tih CYP enzima.
• Sepsis (severe infection in the body and blood stream)/septic shock (serious medical condition which can lead to multiple organ failure and death as a result of sepsis)
• Sepsa (teška infekcija tijela i krvotoka)/septički šok (ozbiljno medicinsko stanje koje može dovesti do zatajenja više organa i smrti uslijed sepse)
In humans, the steady-state volume of distribution of tigecycline averaged 500 to 700 L (7 to 9 L/kg), indicating that tigecycline is extensively distributed beyond the plasma volume and concentrates into tissues.
Kod ljudi je volumen distribucije tigeciklina u stanju dinamičke ravnoteže iznosio prosječno 500 do 700 l (7 do 9 l/kg), što upućuje na to da se tigeciklin opsežno distribuira izvan volumena plazme i koncentrira u tkivima.
Powder for solution for infusion (powder for infusion).
Prašak za otopinu za infuziju (prašak za infuziju).
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.
Detaljne informacije o ovom lijeku dostupne su na web stranici Europske agencije za lijekove: http://www.ema.europa.eu
The in vitro plasma protein binding of tigecycline ranges from approximately 71 % to 89 % at concentrations observed in clinical studies (0.1 to 1.0 mcg/ml).
In vitro vezanje tigeciklina na proteine plazme odvija se u rasponu od otprilike 71% do 89% pri koncentracijama koje su opažene u kliničkim ispitivanjima (0,1 do 1,0 g/ml).
Abdominal pain may be indicative of pancreatitis.
Bol u abdomenu može indicirati pankreatitits.
There is no target-based cross-resistance between tigecycline and most classes of antibiotics.
Ne postoji ciljno utemeljena križna rezistencija između tigeciklina i većine skupina antibiotika.
Species for which acquired resistance may be a problem Gram-negative Aerobes
Vrste kod kojih stečena rezistencija može predstavljati problem
The prevalence of acquired resistance may vary geographically and with time for selected species, and local information on resistance is desirable, particularly when treating severe infections.
Prevalencija stečene rezistencije za pojedine vrste može se razlikovati s obzirom na zemljopisni položaj i vrijeme, te su stoga poželjne lokalne informacije o rezistenciji, posebice ukoliko se radi o liječenju teških infekcija.
Tygacil should be used only in situations where other alternative antibiotics are not suitable (see sections 4.4, 4.8 and 5.1).
Tygacil se može primjenjivati samo u situacijama kada alternativni antibiotici nisu prikladni (vidjeti dijelove 4.4, 4.8 i 5.1).
• Abscess (collection of pus), infections
• Apsces (nakupina gnoja), infekcije
Blood and lymphatic system disorders prolonged activated partial thromboplastin time (aPTT), prolonged prothrombin time (PT)
Poremećaji krvi i limfnog sustava produženo aktivirano parcijalno tromboplastinsko vrijeme (APTV), produženo protrombinsko vrijeme (PV)
Antibiotic class effects
Učinak klase antibiotika
• Tell your doctor immediately if you develop severe abdominal pain, nausea, and vomiting.
• Odmah obavijestite liječnika ako razvijete jaku bol u abdomenu, mučninu i povraćanje.
Concurrent use of antibiotics with oral contraceptives may render oral contraceptives less effective.
Istovremena primjena antibiotika s peroralnim kontraceptivima može umanjiti djelotvornost peroralnih kontraceptiva.
No data are available on whether tigecycline can cross the blood-brain barrier in humans.
Nema dostupnih podataka o tome može li tigeciklin kod ljudi prolaziti kroz krvno-moždanu barijeru.
Abdominal pain is commonly reported in children as it is in adults.
Bol u abdomenu često je prijavljivana u djece i u odraslih.
The results in a large study in patients with diabetic foot infection, showed that tigecycline was less effective than comparator, therefore, tigecycline is not recommended for use in these patients (see section 4.1).
Rezultati velikog ispitivanja u bolesnika s infekcijom dijabetičkog stopala pokazali su da je tigeciklin bio manje učinkovit od terapije s kojom je uspoređivan, zbog toga se tigeciklin ne preporučuje za primjenu kod takvih bolesnika (vidjeti dio 4.1).
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.
Nositelj odobrenja obavljat će dodatne farmakovigilancijske aktivnosti i intervencije, detaljno objašnjene u dogovorenom Planu upravljanja rizikom, a koji je opisan u Modulu 1.8.2 Odobrenja za stavljanje lijeka u promet, te svim sljedećim dogovorenim nadopunama Plana.
Intravenous administration of tigecycline at a single dose of 300 mg over 60 minutes in healthy volunteers resulted in an increased incidence of nausea and vomiting.
Intravenska primjena tigeciklina u zdravih dobrovoljaca u jednokratnoj dozi od 300 mg tijekom 60 minuta dovelo je do povećane incidencije mučnine i povraćanja.
• Poor or slow wound healing
• Slabo ili sporo zacjeljivanje rana
Bone discolouring was observed in rats which was not reversible after two weeks of dosing.
Promjena boje kostiju opažena je kod štakora, no nije bila reverzibilna nakon dva tjedna doziranja.
If you develop another bacterial infection, your doctor may prescribe a different antibiotic specific for the type of infection present.
Ako razvijete drugu bakterijsku infekciju, liječnik će vam možda prepisati drugi antibiotik usmjeren na tu vrstu infekcije.
Tygacil may interfere with the contraceptive pill (birth control pill).
Tygacil može ometati učinak kontracepcijske tablete (tablete protiv začeća).
Uncommon ≥ 1/1,000 to
Manje često ≥ 1/1000 do
Tygacil is an antibiotic of the glycylcycline group that works by stopping the growth of bacteria that cause infections.
Tygacil je antibiotik iz glicilciklinske skupine koji djeluje tako da zaustavlja rast bakterija koje uzrokuju infekcije.
Patients who develop superinfections, in particular nosocomial pneumonia, appear to be associated with poorer outcomes.
Čini se da su bolesnici koji razviju superinfekcije, osobito bolničku pneumoniju, povezani sa slabijim ishodima.
Tygacil is not to be used in children less than 8 years of age due to the lack of data on safety and efficacy in this age group and because it may induce permanent dental defects such as staining on the developing teeth.
Tygacil se ne smije primjenjivati u djece mlađe od 8 godina zbog nedostatka podataka o sigurnosti i djelotvornosti u toj dobnoj skupini i jer može dovesti do trajnog oštećenja zuba, poput mrlja na zubima u razvoju.
Patients should be carefully monitored during therapy (see section 4.8).
Bolesnike je za vrijeme terapije potrebno pažljivo nadzirati (vidjeti dio 4.8).
If you develop diarrhoea during or after your treatment, tell your doctor at once.
Ukoliko dobijete proljev za vrijeme ili nakon liječenja, odmah o tome obavijestite Vašeg liječnika.
Population PK analysis of both studies identified body weight as a covariate of tigecycline clearance in children aged 8 years and older.
Populacijska farmakokinetička analiza u oba ispitivanja utvrdila je da je tjelesna težina kovarijanta klirensa tigeciklina u djece u dobi od 8 godina i starijih.
In severe renal impairment, AUC was 30 % higher than in subjects with normal renal function (see section 4.2).
U slučaju teškog oštećenja bubrega, AUC je bio 30% veći nego kod ispitanika s urednom funkcijom bubrega (vidjeti dio 4.2).
Tigecycline, a glycylcycline antibiotic, inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome.
Tigeciklin, glicilciklinski antibiotik, inhibira translaciju proteina u bakterijama tako što se veže na ribosomsku podjedinicu 30S i blokira ulazak molekula amino-acil-tRNK na mjesto
Very limited safety data were available from two PK studies (see section 5.2).
Dostupni su vrlo ograničeni podaci iz dva farmakokinetička ispitivanja (vidjeti dio 5.2).
Not known side effects are (frequency cannot be estimated from the available data):
Nuspojave nepoznate učestalosti su (učestalost se ne može procijeniti iz dostupnih podataka):
• If you have or previously had any side effects due to antibiotics belonging to the tetracycline class (e.g., skin sensitization to sun light, staining on developing teeth, pancreas inflammation, and alteration of certain laboratory values aimed at measuring how well your blood clots).
• Ukoliko ste prethodno imali bilo kakve nuspojave zbog antibiotika koji pripadaju skupini tetraciklina (npr. preosjetljivost kože na sunce, promjena boje zuba koji rastu, upala gušterače ili promjena nekih laboratorijskih nalaza kojima se određuje kako se zgrušava Vaša krv).
No dosage adjustment is warranted in patients with mild to moderate hepatic impairment (Child Pugh A and Child Pugh B).
Nema potrebe za prilagodbom doze u bolesnika s blagim do umjereno teškim oštećenjem jetre (Child Pugh A i Child Pugh B).
Tigecycline is administered only by intravenous infusion over 30 to 60 minutes (see sections 4.4 and 6.6).
Tigeciklin se primjenjuje isključivo kao intravenska infuzija u trajanju od 30 do 60 minuta (vidjeti dio 4.4 i 6.6).
In vitro studies using Caco-2 cells indicate that tigecycline does not inhibit digoxin flux, suggesting that tigecycline is not a P-glycoprotein (P-gp) inhibitor.
In vitro ispitivanja koristeći Caco-2 stanice ukazuju da tigeciklin ne inhibira protok digoksina, sugerirajući da tigeciklin nije P-glikoproteinski (P-gp) inhibitor.
Decreased susceptibility in Acinetobacter baumannii has been attributed to the overexpression of the AdeABC efflux pump.
Smanjena osjetljivost bakterije Acinetobacter baumannii pripisuje se pretjeranoj ekspresiji AdeABC efluks pumpe.
If you are allergic to tetracycline class antibiotics (e.g., minocycline, doxycycline, etc.), you may be allergic to tigecycline.
Ukoliko ste alergični na tetraciklinsku skupinu antibiotika (npr. minociklin, doksiciklin, itd.), možete biti alergični i na tigeciklin.
Patients usually improve after tigecycline discontinuation.
Bolesnici se obično oporave nakon prekida terapije tigeciklinom.
• Complicated intra-abdominal infections (cIAI).
• Komplicirane intraabdominalne infekcije.
At 4 times the minimum inhibitory concentration (MIC), a 2-log reduction in colony counts was observed with tigecycline against Enterococcus spp., Staphylococcus aureus, and Escherichia coli.
Pri koncentraciji 4 puta većoj od minimalne inhibicijske koncentracije (MIK) tigeciklina, opaženo je smanjenje za 2-log broja kolonija Enterococcus spp., Staphylococcus aureus i Escherichia coli.
Therefore, no breakpoint for susceptibility is given.
Stoga nije moguće navesti graničnu vrijednost osjetljivosti.
• Low blood sugar
• Niska razina šećera u krvi
For instructions on reconstitution & dilution of the medicinal product before administration, see section 6.6.
Za upute o pripremi i razrjeđivanju lijeka prije primjene, vidjeti dio 6.6.
However, systemic clearance of tigecycline was reduced by 25 % and 55 % and the half-life of tigecycline was prolonged by 23 % and 43 % in patients with moderate or severe hepatic impairment (Child Pugh B and C), respectively (see section 4.2).
Međutim, sistemski klirens tigeciklina bio je smanjen za 25%, odnosno 55%, a poluvijek tigeciklina bio je produžen za 23%, odnosno 43% u bolesnika sa srednje teškim, odnosno teškim oštećenjem jetre (Child Pugh B, odnosno C) (vidjeti dio 4.2).
No new or unexpected safety concerns were observed with tigecycline in these studies.
U tim ispitivanjima nisu opažena nova ili neočekivana pitanja u vezi sa sigurnošću primjene tigeciklina.
The diagnosis of acute pancreatitis should be considered in patients taking tigecycline who develop clinical symptoms, signs, or laboratory abnormalities suggestive of acute pancreatitis.
Potrebno je uzeti u obzir dijagnozu akutnog pankreatitisa u bolesnika koji primaju tigeciklin, a koji razvijaju kliničke simptome, znakove ili laboratorijske poremećaje koji upućuju na akutni pankreatitis.
The total clearance of tigecycline is 24 L/h after intravenous infusion.
Ukupni klirens tigeciklina nakon intravenske infuzije iznosi 24 l/h.
Nausea and vomiting are very common adverse reactions in children and adolescents (see section 4.8).
Mučnina i povraćanje vrlo su česte nuspojave u djece i odraslih (vidjeti dio 4.8).
In vitro studies in human liver microsomes indicate that tigecycline does not inhibit metabolism mediated by any of the following 6 cytochrome P450 (CYP) isoforms: 1A2, 2C8, 2C9, 2C19, 2D6, and 3A4 by competitive inhibition.
In vitro ispitivanja s ljudskim jetrenim mikrosomima upućuju na to da tigeciklin ne inhibira metabolizam posredovan bilo kojim od slijedećih 6 izooblika citokroma P450 (CYP): 1A2, 2C8, 2C9, 2C19, 2D6 i 3A4 kompetitivnom inhibicijom.
Glucuronidation and renal excretion of unchanged tigecycline are secondary routes.
Glukuronidacija i izlučivanje nepromijenjenog tigeciklina putem bubrega predstavljaju sekundarne puteve.
In an open-label, single ascending dose PK study, the safety of tigecycline was investigated in 25 children aged 8 to 16 years who recently recovered from infections.
U otvorenom farmakokinetičkom ispitivanju s jednom postupno rastućom dozom sigurnost tigeciklina ispitivana je u 25 djece u dobi od 8 do 16 godina koja su se nedavno oporavila od infekcija.
Clinical experience in the use of tigecycline for the treatment of infections in paediatric patients aged 8 years and older is very limited (see sections 4.8 and 5.1).
Kliničko iskustvo s upotrebom tigeciklina za liječenje infekcija u pedijatrijskih bolesnika u dobi od 8 godina i starijih vrlo je ograničeno (vidjeti dijelove 4.8 i 5.1).
Tigecycline is not extensively metabolised.
Metabolizam tigeciklina nije opsežan.
If pancreatitis develops, treatment with tigecycline should be discontinued.
Ako dođe do pankreatitisa, liječenje tigeciklinom mora se prekinuti.
Tigecycline is able to overcome the two major tetracycline resistance mechanisms, ribosomal protection and efflux.
Tigeciklin može nadvladati dva glavna mehanizma rezistencije kod tetraciklina, ribosomsku zaštitu i efluks.
Race There were no differences in the clearance of tigecycline based on race.
Rasa Nema razlika u klirensu tigeciklina koje se temelje na rasi.
Significant differences in sepsis/septic shock with tigecycline (2.2 %) vs comparators (1.1 %) were observed.
Opažena je značajna razlika u sepsi/septičkom šoku s tigeciklinom (2,2 %) u odnosu na usporedne lijekove (1,1 %).
The single dose pharmacokinetic disposition of tigecycline was not altered in patients with renal insufficiency (creatinine clearance 30 ml/min, n=6).
Farmakokinetička raspoloživost tigeciklina nakon jednokratnog doziranja nije bila promijenjena u bolesnika sa insuficijencijom bubrega (klirens kreatinina<30 ml/min, n=6).
• Low platelet levels in the blood(which may lead to an increased bleeding tendency and bruising/haematoma)
• Niska razina krvnih pločica u krvi (koja može dovesti do povećane sklonosti krvarenju i modricama/hematomima)
In vitro, tigecycline is neither a competitive inhibitor nor an irreversible inhibitor of CYP450 enzymes (see section 5.2).
Tigeciklin nije niti kompetitivni niti ireverzibilni inhibitor enzima CYP450 in vitro (vidjeti dio 5.2).
thrombocytopenia, increased international normalised ratio (INR)
trombocitopenija, povećan međunarodni normalizirani omjer (INR)
Biliary excretion accounts for approximately 50 % of the total tigecycline excretion.
Izlučivanje putem žuči odgovorno je za oko 50% ukupnog izlučivanja tigeciklina.
Inherently resistant organisms
Prirođeno rezistentni organizmi
In general, tigecycline is considered bacteriostatic.
Općenito se tigeciklin smatra bakteriostatskim antibiotikom.
For IV use only
Samo za i.v. primjenu
Overall, the primary route of elimination for tigecycline is biliary excretion of unchanged tigecycline.
Općenito, primarni put eliminacije tigeciklina jest izlučivanje nepromijenjenog tigeciklina putem žuči.
C-labelled tigecycline indicate that tigecycline is excreted readily via the milk of lactating rats.
C-označen tigeciklin upućuju na to da se tigeciklin brzo izlučuje putem mlijeka štakorica tijekom laktacije.
Available pharmacodynamic/toxicological data in animals have shown excretion of tigecycline/metabolites in milk (see section 5.3).
Dostupni farmakodinamički/toksikološki podaci u životinja pokazuju da se tigeciklin/metaboliti izlučuju u mlijeko (za detalje vidjeti 5.3).
Overgrowth of non-susceptible organisms, including fungi (see section 4.4).
Prekomjerni rast neosjetljivih mikroorganizama, uključujući gljivice (vidjeti dio 4.4).
The recovery of the total radioactivity in faeces and urine following administration of
Ukupna radioaktivnost koju je moguće pronaći u stolici i urinu nakon primjene
Once the powder has been made into a solution and diluted ready for use, it should be given to you immediately.
Nakon što se prašak otopi i pripremljena otopina razrijedi, spremna je za primjenu i potrebno ju se odmah primijeniti.
Limited experience is also available in treating patients with concurrent bacteraemia (5.6 %).
Također postoji ograničeno iskustvo u liječenju bolesnika s istovremenom bakterijemijom (5,6%).
Metabolism and nutrition disorders hypoglycaemia, hypoproteinaemia
Poremećaji metabolizma i prehrane hipoglikemija, hipoproteinemija
Elderly No dosage adjustment is necessary in elderly patients (see section 5.2).
Nije potrebna prilagodba doze u starijih bolesnika (vidjeti dio 5.2).
Tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections (see sections 4.4 and 5.1):
Tygacil je indiciran u odraslih i u djece starije od osam godina za liječenje sljedećih infekcija (vidjeti dijelove 4.4 i 5.1):
The use of tigecycline may result in overgrowth of non-susceptible organisms, including fungi.
Primjena tigeciklina može dovesti do pretjeranog rasta organizama koji nisu osjetljivi na ovaj lijek, uključujući gljivice.
There were a limited number of patients with severe underlying disease such as immunocompromised patients, patients with APACHE II scores  15 (3.3 %), or with surgically apparent multiple intra-abdominal abscesses (11.4 %).
Uključen je ograničen broj bolesnika s teškom osnovnom bolešću, poput imunokompromitiranih bolesnika, bolesnika s APACHE II bodovima > 15 (3,3%) ili kirurški verificiranim višestrukim intraabdominalnim apscesima (11,4%).
Read the package leaflet before use for directions on reconstitution and dilution.
Prije uporabe pročitati Uputu o lijeku za smjernice oko pripreme i razrjeđivanja.
In clinical trials, the most common medicinal product-related treatment emergent adverse reactions were reversible nausea (21 %) and vomiting (13 %), which usually occurred early (on treatment days 1-2) and were generally mild or moderate in severity.
U kliničkim ispitivanjima najčešće nuspojave povezane s lijekom bile su mučnina (21%) i povraćanje (13%), koje su se obično javljale rano (1.- 2. dan liječenja) i općenito su bile blage do umjereno teške.
After reconstitution, 1 ml contains 10 mg of tigecycline.
Nakon pripreme, 1 ml sadrži 10 mg tigeciklina.
Experience in the use of tigecycline for treatment of infections in patients with severe underlying diseases is limited.
Iskustvo s primjenom tigeciklina u liječenju infekcija u bolesnika s teškim osnovnim bolestima je ograničeno.
Thus, 5 ml of reconstituted solution is equivalent to 50 mg of the active substance.
Stoga 5 ml pripremljene otopine odgovara 50 mg djelatne tvari.
If this were the case, your doctor will monitor you closely.
U tom će Vas slučaju liječnik češće kontrolirati.
• Complicated infection of the skin and soft tissues (the tissue below the skin), excluding diabetic foot infections.
• Kompliciranu infekciju kože i mekih tkiva (tkiva ispod kože), ne uključujući infekcije dijabetičkog stopala
• Increases in liver enzymes, hyperbilirubinaemia (excess of bile pigment in the blood)
• Porast jetrenih enzima, hiperbilirubinemija (višak žučnog pigmenta u krvi)
Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:
Europska komisija za ispitivanje osjetljivosti na antimikrobne lijekove (EUCAST, European Committee on Antimicrobial Susceptibility Testing) utvrdila je sljedeće granične vrijednosti minimalne inhibicijske koncentracije (MIK):
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
POSEBNE MJERE ZA ZBRINJAVANJE E NEISKORIŠTENOG LIJEKA ILI OTPADNIH MATERIJALA KOJI POTJEČU
The steady-state AUC0-12h was 2349±850 ng•h/ml.
AUC0-12h u stanju dinamičke ravnoteže iznosio je 2349±850 ng•h/ml.
If you are concerned that you may have been given too much Tygacil, talk to your doctor or nurse immediately.
Ako Vas brine to da ste možda primili previše Tygacila, odmah razgovarajte s Vašim liječnikom ili medicinskom sestrom.
C-labelled material recovered in urine and faeces, but a glucuronide, an N-acetyl metabolite and a tigecycline epimer were also present.
C-označenog materijala koji se mogao naći u urinu i stolici, ali bili su prisutni i glukuronid, N-acetilski metabolit, kao i epimer tigeciklina.
In clinical trials in cIAI, the most common type of infection in tigecycline-treated patients was complicated appendicitis (50.3 %), followed by other diagnoses less commonly reported such as complicated cholecystitis (9.6 %), perforation of intestine (9.6 %), intra-abdominal abscess (8.7 %), gastric or duodenal ulcer perforation (8.3 %), peritonitis (6.2 %) and complicated diverticulitis (6.0 %).
U kliničkim ispitivanjima s cIAI-ovima (engl. complicated intra-abdominal infections), najčešći oblik infekcije u bolesnika koji su liječeni tigeciklinom bio je komplicirani apendicitis (50,3%), a potom slijede ostale rjeđe prijavljene dijagnoze poput kompliciranog kolecistitisa (9,6%), perforacija crijeva (9,6%), intraabdominalnog apscesa (8,7%), perforacije želučanog ili duodenalnog ulkusa (8,3%), peritonitis (6,2%) i komplicirani divertikulitis (6,0%).